RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19

 RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19

RedHill Biopharma’s Talicia Received the US FDA’s Approval for H. pylori in Adults

Shots:

  • RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19
  • Additionally, RedHill is evaluating opaganib (Yeliva, ABC294640) against COVID-19. On Apr 17, the company unveils about the compassionate use of Opaganib is underway in Israel, with several patients treated to date and preliminary positive outcomes
  • RHB-107 is a serine protease inhibitor active against trypsins and other related serine proteases, being evaluated in 300+ people across 10 clinical studies, including two completed P-II studies in oncology patients and multiple P-I studies in healthy volunteers and oncology patients

Click here ­to­ read full press release/ article | Ref: RedHill | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post